Study examines immunotherapy and cerebrospinal fluid biomarkers in patients with Alzheimer's disease

April 2, 2012

Immunotherapy with the antibody bapineuzumab in patients with mild to moderate Alzheimer disease resulted in decreases in a cerebrospinal fluid biomarker, which may indicate downstream effects on the degenerative process, according to a report published Online First by Archives of Neurology.

Alzheimer disease (AD) is a progressive neurodegenerative disease characterized by, among other things, deposits of extracellular β-amyloid (Αβ) plaques and intraneuronal neurofibrillary tangles with accompanying decreases in (CSF) Αβ and increases in CSF tau proteins. Bapineuzumab is an anti-Αβ monoclonal antibody, and immunotherapy with against Αβ is one of the major disease-modifying therapeutic approaches being evaluated for AD, the authors write in their study background.

Kaj Blennow, M.D., Ph.D., of the University of Gothenburg, Sweden, and colleagues conducted a combined analysis of two double-blind, placebo-controlled trials that included 46 patients with mild to moderate AD. A total of 27 patients were treated with bapineuzumab and 19 with placebo. The researchers evaluated whether bapineuzumab affected the CSF levels of the downstream biomarkers, total tau (T-tau) and phosphorylated tau (P-tau), and the primary biomarker Αβ in the completed trials.

"The reduction in the downstream CSF P-tau following treatment with bapineuzumab suggests that bapineuzumab reduces brain levels of P-tau, which may also reduce the formation of tangles in the brain," the authors note.

Although there was a reduction in CSF T-tau, it did not reach statistical significance compared with placebo. No clear-cut differences were observed for CSF Αβ, the study results indicate. But the observed decrease in both P-tau and T-tau require further examination, the authors note.

"An important question remains whether such changes in CSF biomarkers correlate with clinical benefit. This question will be addressed in the ongoing bapineuzumab phase 3 trials," the authors conclude.

Explore further: Clinical trial examines antioxidant effects for Alzheimer's disease on cerebrospinal fluid biomarkers

More information: Arch Neurol. Published online April 2, 2012. doi:10.1001/archneurol.2012.90

Related Stories

Clinical trial examines antioxidant effects for Alzheimer's disease on cerebrospinal fluid biomarkers

March 19, 2012
An antioxidant combination of vitamin E, vitamin C and α-lipoic acid (E/C/ALA) was not associated with changes in some cerebrospinal fluid biomarkers related to Alzheimer disease in a randomized controlled trial, according ...

Changes seen in cerebrospinal fluid levels before onset of Alzheimer dementia

January 2, 2012
Cerebrospinal fluid levels of Aβ42 appear to be decreased at least five to 10 years before some patients with mild cognitive impairment develop Alzheimer disease (AD) dementia whereas other spinal fluid levels seem to ...

Recommended for you

Lifestyle changes to stave off Alzheimer's? Hints, no proof

July 20, 2017
There are no proven ways to stave off Alzheimer's, but a new report raises the prospect that avoiding nine key risks starting in childhood just might delay or even prevent about a third of dementia cases around the world.

Blood test identifies key Alzheimer's marker

July 19, 2017
A new study led by researchers at Washington University School of Medicine in St. Louis suggests that measures of amyloid beta in the blood have the potential to help identify people with altered levels of amyloid in their ...

Steering an enzyme's 'scissors' shows potential for stopping Alzheimer's disease

July 19, 2017
The old real estate adage about "location, location, location" might also apply to the biochemical genesis of Alzheimer's disease, according to new research from the University of British Columbia.

Brain scans may change care for some people with memory loss

July 19, 2017
Does it really take an expensive brain scan to diagnose Alzheimer's? Not everybody needs one but new research suggests that for a surprising number of patients whose memory problems are hard to pin down, PET scans may lead ...

Can poor sleep boost odds for Alzheimer's?

July 18, 2017
(HealthDay)— Breathing problems during sleep may signal an increased risk for Alzheimer's disease, a trio of studies suggests.

Hearing is believing: Speech may be a clue to mental decline

July 17, 2017
Your speech may, um, help reveal if you're uh ... developing thinking problems. More pauses, filler words and other verbal changes might be an early sign of mental decline, which can lead to Alzheimer's disease, a study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.